AD/PD 2021 | Important considerations for APOE disclosure in AD risk assessment

As research in early Alzheimer’s disease (AD) progresses and the ability to predict memory loss improves, patient understanding and ability to tolerate information about disease risk is an important consideration. Stephen Salloway, MD, MS, Butler Hospital and Brown University, Providence, RI, outlines a study of the safety and tolerability of APOE disclosure in cognitively normal older adults. Following readiness screening and genotyping, the study assessed self-reported measures of depression, anxiety, perceived AD risk, and clinical trial participation. APOE disclosure was shown to be well tolerated and did not impact participation in clinical trials. This interview took place during the AD/PD™ 2021 conference.